Loading people...
Henry Brem is the Harvey Cushing Professor and Director of the Department of Neurosurgery at Johns Hopkins Medicine in Baltimore, Maryland. He earned his Doctor of Medicine from Harvard Medical School and a Bachelor of Arts in Biology from New York University. As a pioneering neurosurgeon and researcher, he helped develop the FDA approved Gliadel wafer for localized brain tumor chemotherapy and has authored hundreds of peer reviewed publications. Under his leadership, the neurology and neurosurgery specialty at Johns Hopkins Hospital secured the number one national ranking by US News and World Report for 2023 to 2024. Elected to the National Academy of Medicine in 1998 and the American Academy of Arts and Sciences in April 2021, his career focuses on advancing neuro-oncology, biotechnology, medical devices, and academic medicine through clinical practice and targeted drug delivery.
Henry Brem is a distinguished Venture Partner at Catalio Capital, a leading multi-strategy investment firm focused on the healthcare and life sciences industries. In this pivotal role, Dr. Brem brings an unparalleled depth of scientific and clinical expertise, honed over decades as a world-renowned neurosurgeon and researcher. His unique perspective is instrumental in identifying and evaluating early-stage and growth-stage companies that are poised to revolutionize patient care.
Dr. Brem's investment focus areas at Catalio Capital are deeply rooted in his medical background, primarily encompassing biotechnology, medical devices, neurosciences, oncology, and other high-impact areas within healthcare. He is particularly adept at assessing the scientific rigor, clinical potential, and market viability of novel therapies and technologies. His contributions ensure that Catalio's investment decisions are informed by a profound understanding of medical science and patient needs.
Before joining Catalio Capital, Dr. Brem built an illustrious career at Johns Hopkins University School of Medicine. He is widely recognized for his pioneering work in neurosurgery, particularly in the treatment of brain tumors. As the Harvey Cushing Professor of Neurosurgery, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief at Johns Hopkins Hospital, he led significant advancements in the field. His groundbreaking research on drug delivery systems for brain tumors, including the development of Gliadel wafer, a biodegradable polymer that delivers chemotherapy directly to the tumor site, has had a lasting impact on neuro-oncology. This innovation exemplifies his commitment to translating scientific discovery into tangible patient benefits.
Throughout his career, Dr. Brem has authored hundreds of peer-reviewed articles and holds numerous patents, underscoring his prolific contributions to medical science. His extensive network within the academic, medical, and pharmaceutical communities further enhances his ability to source and vet promising ventures for Catalio Capital. While specific individual investments are often a collaborative effort within Catalio, Dr. Brem's scientific acumen is critical in shaping the firm's portfolio, guiding investments towards companies developing truly transformative solutions in areas like targeted cancer therapies, advanced neurosurgical tools, and innovative drug delivery platforms. His involvement ensures that Catalio Capital remains at the forefront of healthcare innovation, supporting companies that not only offer financial returns but also hold the promise of significantly improving human health.
Henry Brem is a highly respected neurosurgeon, scientist, and Venture Partner at Catalio Capital. He is renowned for his pioneering work in neuro-oncology and for applying his extensive medical and scientific expertise to identify and evaluate investment opportunities in the healthcare and life sciences sectors.
As a Venture Partner at Catalio Capital, Henry Brem focuses on investments in biotechnology, medical devices, neurosciences, oncology, and other high-impact areas within healthcare. He leverages his scientific and clinical insights to assess novel therapies and technologies with significant patient impact potential.
Henry Brem works as a Venture Partner at Catalio Capital, a multi-strategy investment firm specializing in healthcare and life sciences. Prior to this, he had a distinguished career at Johns Hopkins University School of Medicine, where he served as the Harvey Cushing Professor of Neurosurgery and Neurosurgeon-in-Chief.
